Also trades as: AGY.L (LSE) · $vol 0M
AGYTF OTC
Allergy Therapeutics plc
1W: +0.0%
1M: +0.0%
3M: +7.1%
YTD: +36.4%
1Y: +76.5%
3Y: -38.3%
5Y: -31.8%
$0.15
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
-$39M
-22.7% ▼
Capital Expenditures
$4M
-31.8% ▼
5Y CAGR: +12.0%
Free Cash Flow
-$44M
-23.5% ▼
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
$1M
+163.7% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $4M | -$13M | -$42M | -$39M | -$39M |
| Depreciation & Amort. | $4M | $4M | $4M | $4M | $4M |
| Stock-Based Comp. | $635K | $469K | $114K | $759K | $871K |
| Change in Working Capital | $2M | -$6M | $5M | -$307K | -$3M |
| Other Non-Cash Items | $374K | $412K | $4M | $2M | -$2M |
| Operating Cash Flow | $8M | -$14M | -$29M | -$32M | -$39M |
| — Investing Activities — | |||||
| Capital Expenditures | -$3M | -$3M | -$5M | -$3M | -$3M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 |
| Investment Purchases | -$194K | -$179K | -$159K | $0 | $0 |
| Investment Sales | $0 | $0 | $0 | $2M | $267K |
| Other Investing | $117K | $257K | $241K | $135K | -$1M |
| Investing Cash Flow | -$3M | -$3M | -$5M | -$1M | -$4M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$132K | -$957K | $25M | $34M | $35M |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | -$2M | -$2M | -$4M | -$5M | $9M |
| Financing Cash Flow | -$2M | -$3M | $28M | $31M | $44M |
| Net Change in Cash | $3M | -$20M | -$6M | -$2M | $1M |
| Cash End of Period | $40M | $21M | $15M | $13M | $18M |
| Free Cash Flow | $6M | -$18M | -$34M | -$36M | -$44M |